POLARIS INSIGHTS

Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

Merck's immunotherapy Keytruda, including a newer injectable form of the drug.

Read the full account of the story

More from Markets · Back to Polaris Insights